$ILMN News

Is Illumina’s (ILMN) Deeper IDT DRAGEN Tie-Up Quietly Rewriting Its Oncology Software Edge?

ILMN Stock Jumps 98.7% in a Year: What's Powering the Surge?

Integrated DNA Technologies Announces Strategic Collaboration With Illumina To Enable DRAGEN Secondary Analysis Pipeline For IDT xGen FFPE And cfDNA Next Gen Sequencing Library Preparation With Custom Panels

Guggenheim Maintains Buy on Illumina, Raises Price Target to $180

Illumina and SPT Labtech unveil fireflyGO, enabling faster, simpler targeted oncology research

Illumina introduces the first distributed whole-genome sequencing solution for highly sensitive MRD research

Illumina Announces New Complete Solution For Molecular Residual Disease Research Based On Whole-Genome Sequencing

Illumina (ILMN) Valuation Check After Strong Recent Share Price Momentum

3 Reasons to Sell ILMN and 1 Stock to Buy Instead

Is This the Right Time to Retain ILMN Stock in Your Portfolio?

Earnings Beat, Buyback, China Signals Might Change The Case For Investing In Illumina (ILMN)

Illumina releases 2025 Corporate Responsibility Report, expanding access to genomics and accelerating global impact

This Beaten-Down Growth Stock Could Soar 30%, According to Wall Street

Illumina's Mid-Teens Clinical Growth Appears Sustainable Over Next 1 to 2 Years, RBC Says

RBC Capital Reinstates Outperform on Illumina, Announces $170 Price Target

Is Illumina (ILMN) Pricing Look Interesting After 77% One Year Share Price Gain

Natera’s Stronghold in Cancer Recurrence Tests Prompts Wood’s Ark to Expand Stake

Pacific Biosciences of California Q1 Earnings Call Highlights

Assessing Illumina (ILMN) Valuation After Earnings Beat Guidance Hike And Expanded Buyback

PacBio Pre-Q1 Analysis: Time to Buy, Hold or Sell the Stock Now?